312 related articles for article (PubMed ID: 27770867)
1. Stability of (-)-epigallocatechin gallate and its activity in liquid formulations and delivery systems.
Krupkova O; Ferguson SJ; Wuertz-Kozak K
J Nutr Biochem; 2016 Nov; 37():1-12. PubMed ID: 27770867
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of (-)-epigallocatechin gallate into liposomes and into alginate or chitosan microparticles reinforced with liposomes.
Istenič K; Cerc Korošec R; Poklar Ulrih N
J Sci Food Agric; 2016 Oct; 96(13):4623-32. PubMed ID: 26921243
[TBL] [Abstract][Full Text] [Related]
3. Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate.
Fangueiro JF; Parra A; Silva AM; Egea MA; Souto EB; Garcia ML; Calpena AC
Int J Pharm; 2014 Nov; 475(1-2):181-90. PubMed ID: 25175728
[TBL] [Abstract][Full Text] [Related]
4. Production of monodisperse epigallocatechin gallate (EGCG) microparticles by spray drying for high antioxidant activity retention.
Fu N; Zhou Z; Jones TB; Tan TT; Wu WD; Lin SX; Chen XD; Chan PP
Int J Pharm; 2011 Jul; 413(1-2):155-66. PubMed ID: 21554936
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of EGCG: a patent review.
Chakrawarti L; Agrawal R; Dang S; Gupta S; Gabrani R
Expert Opin Ther Pat; 2016 Aug; 26(8):907-16. PubMed ID: 27338088
[TBL] [Abstract][Full Text] [Related]
6. Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles.
Tyagi N; De R; Begun J; Popat A
Int J Pharm; 2017 Feb; 518(1-2):220-227. PubMed ID: 27988378
[TBL] [Abstract][Full Text] [Related]
7. A Poloxamer-407 modified liposome encapsulating epigallocatechin-3-gallate in the presence of magnesium: Characterization and protective effect against oxidative damage.
Minnelli C; Moretti P; Fulgenzi G; Mariani P; Laudadio E; Armeni T; Galeazzi R; Mobbili G
Int J Pharm; 2018 Dec; 552(1-2):225-234. PubMed ID: 30291957
[TBL] [Abstract][Full Text] [Related]
8. Preservation of (-)-epigallocatechin-3-gallate antioxidant properties loaded in heat treated β-lactoglobulin nanoparticles.
Li B; Du W; Jin J; Du Q
J Agric Food Chem; 2012 Apr; 60(13):3477-84. PubMed ID: 22409289
[TBL] [Abstract][Full Text] [Related]
9. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin cancer prevention.
Proniuk S; Liederer BM; Blanchard J
J Pharm Sci; 2002 Jan; 91(1):111-6. PubMed ID: 11782902
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention.
Rocha S; Generalov R; Pereira Mdo C; Peres I; Juzenas P; Coelho MA
Nanomedicine (Lond); 2011 Jan; 6(1):79-87. PubMed ID: 21182420
[TBL] [Abstract][Full Text] [Related]
11. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.
Frias I; Neves AR; Pinheiro M; Reis S
Drug Des Devel Ther; 2016; 10():3519-3528. PubMed ID: 27826184
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems.
Granja A; Frias I; Neves AR; Pinheiro M; Reis S
Biomed Res Int; 2017; 2017():5813793. PubMed ID: 28791306
[TBL] [Abstract][Full Text] [Related]
13. Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer.
Radhakrishnan R; Kulhari H; Pooja D; Gudem S; Bhargava S; Shukla R; Sistla R
Chem Phys Lipids; 2016 Jun; 198():51-60. PubMed ID: 27234272
[TBL] [Abstract][Full Text] [Related]
14. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells.
Hong J; Lu H; Meng X; Ryu JH; Hara Y; Yang CS
Cancer Res; 2002 Dec; 62(24):7241-6. PubMed ID: 12499265
[TBL] [Abstract][Full Text] [Related]
15. Photodegradation of (-)-epigallocatechin-3-gallate in topical cream formulations and its photostabilization.
Bianchi A; Marchetti N; Scalia S
J Pharm Biomed Anal; 2011 Dec; 56(4):692-7. PubMed ID: 21807473
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of different co-antioxidants on the photochemical- and functional-stability of epigallocatechin-3-gallate in topical creams exposed to simulated sunlight.
Scalia S; Marchetti N; Bianchi A
Molecules; 2013 Jan; 18(1):574-87. PubMed ID: 23292326
[TBL] [Abstract][Full Text] [Related]
17. Niosomes Consisting of Tween-60 and Cholesterol Improve the Chemical Stability and Antioxidant Activity of (-)-Epigallocatechin Gallate under Intestinal Tract Conditions.
Liang R; Chen L; Yokoyama W; Williams PA; Zhong F
J Agric Food Chem; 2016 Dec; 64(48):9180-9188. PubMed ID: 27933988
[TBL] [Abstract][Full Text] [Related]
18. Protonation of epigallocatechin-3-gallate (EGCG) results in massive aggregation and reduced oral bioavailability of EGCG-dispersed selenium nanoparticles.
Wu S; Sun K; Wang X; Wang D; Wan X; Zhang J
J Agric Food Chem; 2013 Jul; 61(30):7268-75. PubMed ID: 23822637
[TBL] [Abstract][Full Text] [Related]
19. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability.
Dube A; Nicolazzo JA; Larson I
Eur J Pharm Sci; 2011 Oct; 44(3):422-6. PubMed ID: 21925598
[TBL] [Abstract][Full Text] [Related]
20. Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions.
Sang S; Lee MJ; Hou Z; Ho CT; Yang CS
J Agric Food Chem; 2005 Nov; 53(24):9478-84. PubMed ID: 16302765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
